Patents by Inventor Gustav Oberdorfer

Gustav Oberdorfer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • De novo designed non-local beta sheet proteins
    Patent number: 11802141
    Abstract: Beta-sheet forming polypeptides at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS:1-24 are disclosed, together with their use and methods for designing beta-sheet forming polypeptides.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: October 31, 2023
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: Tamuka Chidyausiku, Enrique Marcos, Lucas Nivon, Gustav Oberdorfer, David Baker, Lauren Carter
  • AMANTADINE BINDING PROTEIN
    Publication number: 20220185853
    Abstract: Disclosed herein are amantadine binding polypeptides, fusion proteins thereof, and uses of such polypeptides and fusion proteins.
    Type: Application
    Filed: April 15, 2020
    Publication date: June 16, 2022
    Inventors: Jooyoung PARK, Scott BOYKEN, Kathy WEI, Gustav OBERDORFER, David BAKER
  • De Novo Designed Non-Local Beta Sheet Proteins
    Publication number: 20210122793
    Abstract: Beta-sheet forming polypeptides at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS:1-24 are disclosed, together with their use and methods for designing beta-sheet forming polypeptides.
    Type: Application
    Filed: October 23, 2020
    Publication date: April 29, 2021
    Inventors: Tamuka CHIDYAUSIKU, Enrique MARCOS, Lucas NIVON, Gustav OBERDORFER, David BAKER, Lauren CARTER
  • Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
    Patent number: 10688330
    Abstract: A genetically modified polypeptide is disclosed which comprises an amino acid sequence of phosphotriesterase (PTE) having at least twice the catalytic efficiency for a V-type nerve agent as a polypeptide which consists of the sequence as set forth in SEQ ID NO: 1, when assayed under identical conditions.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: June 23, 2020
    Assignees: Yeda Research and Development Co. Ltd., University of Washington
    Inventors: Dan S. Tawfik, Haim Leader, Yaacov Ashani, Izhack Cherny, Moshe Goldsmith, Per Jr. Greisen, Sagar D. Khare, Gustav Oberdorfer, David Baker, Sarel Fleishman, Adi Goldenzweig, Nidhi Aggarwal
  • ISOLATED PHOSPHOTRIESTERASE POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF IN TREATING OR PREVENTING ORGANOPHOSPHATE EXPOSURE ASSOCIATED DAMAGE
    Publication number: 20190083836
    Abstract: A genetically modified polypeptide is disclosed which comprises an amino acid sequence of phosphotriesterase (PTE) having at least twice the catalytic efficiency for a V-type nerve agent as a polypeptide which consists of the sequence as set forth in SEQ ID NO: 1, when assayed under identical conditions.
    Type: Application
    Filed: December 10, 2015
    Publication date: March 21, 2019
    Inventors: Dan S. TAWFIK, Haim LEADER, Yaacov ASHANI, Izhack CHERNY, Moshe GOLDSMITH, Per Jr. GRIESEN, Sagar D KHARE, Gustav Oberdorfer, David Baker, Sarel Fleishman, Adi Goldenzweig, Nidhi Aggarwal